Continue to Site

Drug Discovery and Development

The most innovative pharmaceutical agents of 2020

By |

reyvowReyvow

Eli Lilly and Company

Reyvow is a prescription medication that is used for the acute treatment of migraine attacks with or without aura in adults.

Eli Lilly and Company’s Reyvow is a 5-HT1F serotonin receptor agonist that binds with high affinity to the 5-HT1F receptor, which is thought to be a cause of migraines.

Common side effects can include dizziness, sleepiness, numbness, feeling tired and tinging.

Next >>

Filed Under: Drug Discovery, Drug Discovery and Development, Neurological Disease, Oncology, Orphan Drugs
Tagged With: , , , , , , , , , , , , , , , , , , , , , , , ,
 

About The Author

Danielle Kirsh

Danielle Kirsh is an award-winning journalist and senior editor for Medical Design & Outsourcing, MassDevice, and Medical Tubing + Extrusion, and the founder of Women in Medtech and lead editor for Big 100. She received her bachelor's degree in broadcast journalism and mass communication from Norfolk State University and is pursuing her master's in global strategic communications at the University of Florida. You can connect with her on Twitter and LinkedIn, or email her at dkirsh@wtwhmedia.com.

Tell Us What You Think!

Related Articles Read More >

Search Drug Discovery & Development